Can you chip in? This year we’ve reached an extraordinary milestone: 1 trillion web pages preserved on the Wayback Machine. This makes us the largest public repository of internet history ever ...

Background: Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are common diagnoses in patients attending chest clinics, but little is known about the epidemiology of these diseases. We used data ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...

The FDA has approved Boehringer Ingelheim’s twice-daily pill nerandomilast for the treatment of idiopathic pulmonary fibrosis. The drug will carry the brand name Jascayd. According to the FDA’s ...

Jascayd is the first new IPF therapy approved in over 10 years, addressing a rare and serious disease with limited treatments. FDA approval was based on Phase III trials showing reduced FVC decline ...

Jascayd’s approval adds to Boehringer’s already prominent position in treating IPF. In 2014, the company won an FDA clearance for Ofev, which has become a pillar of care for IPF and one of ...

If Canon really does drop this lens next month, it'll mark a big step forward for RF shooters – especially those who've been waiting for a zoom lens with serious reach, speed, and pro-grade ...

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming ...

特发性肺纤维化（idiopathic pulmonary fibrosis，IPF）是特发性间质性肺炎的一个亚型，病变局限于肺部，组织病理学和（或）影像学表现具有寻常型间质性肺（usual interstitial pneumonia, UIP）的特征。IPF患者诊断后的中位生存时间是 3～4 年，自然病程具有异质性，可分为 ...